日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

  Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N- trimethylpropylammonium in chronic myeloid leukemia cell lines

Konstantinov, S. M., Georgieva, M. C., Topashka-Ancheva, M., Eibl, H., & Berger, M. R. (2002). Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N- trimethylpropylammonium in chronic myeloid leukemia cell lines. Molecular Cancer Therapeutics, 1(10), 877-884.

Item is

基本情報

表示: 非表示:
資料種別: 学術論文

ファイル

表示: ファイル

関連URL

表示:

作成者

表示:
非表示:
 作成者:
Konstantinov, S. M., 著者
Georgieva, M. C., 著者
Topashka-Ancheva, M., 著者
Eibl, H.1, 著者           
Berger, M. R., 著者
所属:
1Research Group of Phospholipids, MPI for biophysical chemistry, Max Planck Society, ou_578562              

内容説明

表示:
非表示:
キーワード: -
 要旨: The aim of this study was to enhance the antileukemic efficacy of the alkylphosphocholine erucylphospho-N,N,N- trimethylpropylammonium (ErPC3) in chronic myeloid leukemia (CML)-derived cell lines by a bcr-directed antisense oligonucleotide (ASO-bcr). The mechanism was substantiated by Western blotting of the BCR-ABL expression level of CML cells, and the efficacy was substantiated by inhibition of colony formation compared with normal hematopoietic cells. The clonogenicity of K-562 cells expressing high levels of p210(BCR-ABL) was inhibited significantly by the ASO-bcr (T/C%, 30; P < 0.05) but not by ErPC3 (T/C%, 70). Combined sequential exposure to ErPC3 and the ASO-bcr, however, inhibited synergistically colony growth (T/C%, 3; P < 0.01). The colony growth of BV-173 cells expressing lower levels of p210(BCR-ABL) than K562 cells was inhibited to a greater extent by the ASO- bcr (T/C%, 15; P < 0.01). AR-230 cells that express high levels of p230(BCR-ABL) showed an intermediate decrease in colony formation in response to the ASO-bcr (T/C%, 20; P < 0.05). BCR- ABL levels of BV-173, CML-T1, and LAMA-84 cells were reduced in response to the ASO-bcr, as evidenced by Western blot. However, K-562 and AR-230 cells showed reduced BCR-ABL expression only after repeated treatment. ErPC3 and the ASO-bcr did not reduce colony formation (CFU-GM) of normal mouse bone marrow cells from long-term bone marrow cell cultures; instead, ErPC3 stimulated colony formation (P < 0.05) and did not induce chromosomal aberrations in mouse bone marrow. In conclusion, the combination of ErPC3 with a suitable antisense oligonucleotide inhibited synergistically colony formation of CML cell lines without damaging normal cells and thus might have a bearing on the purging of autologous hematopoietic transplants in CML patients.

資料詳細

表示:
非表示:
言語: eng - English
 日付: 2002-08
 出版の状態: 出版
 ページ: -
 出版情報: -
 目次: -
 査読: 査読あり
 識別子(DOI, ISBNなど): eDoc: 16686
 学位: -

関連イベント

表示:

訴訟

表示:

Project information

表示:

出版物 1

表示:
非表示:
出版物名: Molecular Cancer Therapeutics
種別: 学術雑誌
 著者・編者:
所属:
出版社, 出版地: -
ページ: - 巻号: 1 (10) 通巻号: - 開始・終了ページ: 877 - 884 識別子(ISBN, ISSN, DOIなど): -